Evidence map›Paper›PMID 42427150›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2026

Self-Cooperative RNA Vaccine Mitigates Dendritic Cell-Mediated Acquired Immune Resistance to Potentiate Cell Therapy for Solid Tumors.

Lujia Huang, Fangmin Chen, Feng Zhou, Gujia Mao, Wenyue Lan, Mengfan Li, Shiqin Li, Jing Gao, Zhixiong Cai, Andong Liu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lujia HuangState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID https://orcid.org/0000-0002-9574-9174
Fangmin ChenState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Feng ZhouState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Gujia MaoState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Wenyue LanState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Mengfan LiState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Shiqin LiState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jing GaoState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Zhixiong CaiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Andong LiuMetis Pharmaceutical, Beijing, China.
Wenshou WangMetis Pharmaceutical, Beijing, China.
Zhiai XuSchool of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Bo HouState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xiaolong LiuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Haijun YuState Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID https://orcid.org/0000-0002-3398-0880

Funding

National Facility for Protein Science in ShanghaiNational Natural Science Foundation of China 22074043National Natural Science Foundation of China 22505284National Natural Science Foundation of China U22A20328National Natural Science Foundation of China W2412035Science and Technology Commission of Shanghai Municipality 23ZR1475000Science and Technology Commission of Shanghai Municipality 24430713500
6 · The paper itself

Abstract

Conventional mRNA cancer vaccines are designed to maximize antigen potency but often overlook vaccination-induced immune resistance. In this study, we identified a negative immune regulatory mechanism, whereby mRNA vaccination induces programmed death-ligand 1 (PD-L1) expression in dendritic cells (DCs) through type I interferon (IFN-I) signaling. Elevated PD-L1 expression impairs T-cell priming in lymph nodes through engagement of programmed death receptor 1 (PD-1) on T lymphocytes. To address this challenge, we developed a self-cooperative RNA vaccine (SCORV) strategy by co-delivering antigen-encoding RNA and small interfering RNA against PD-L1 (siPD-L1) within a single lipid nanoparticle (LNP). Through iterative screening of >300 ionizable lipids, we optimized a DC-targeted LNP formulation with high RNA delivery efficiency and minimal immunotoxicity. SCORV simultaneously suppresses PD-L1-mediated immune resistance during antigen presentation and enhances T cell priming while alleviating T cell exhaustion. Importantly, SCORV potentiates the tumor reactivity of adoptively transferred tumor-infiltrating lymphocytes and elicits robust antitumor immunity in murine melanoma and hepatocellular carcinoma models. This work highlights a rational design principle for mRNA vaccines that self-correct vaccination-induced immune resistance.

Indexed as

Cancer VaccinesDendritic CellsmRNA VaccinesAnimalsB7-H1 AntigenCell Line, TumorInterferon Type ILipidsLiposomesMiceMice, Inbred C57BLNanoparticlesRNA, Small InterferingT-LymphocytesB7-H1 AntigenCancer VaccinesInterferon Type ILipid NanoparticlesLipidsLiposomesmRNA VaccinesRNA, Small Interferinglipid nanoparticlesmRNA cancer vaccinenegative immune regulationRNA interferencetumor‐infiltrating lymphocyte therapy

Identifiers

PMID42427150
PMCPMC13486277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.